Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
Status:
Withdrawn
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of image-guided adaptive radiation
therapy using active breathing control when given together with chemotherapy and simultaneous
integrated boost in treating patients with stage IIA-IIIB non-small cell lung cancer that
cannot be removed by surgery. Image-guided adaptive radiation therapy aims radiation therapy
right at the tumor so that higher radiation doses can be given without causing bad side
effects. Giving these higher doses may help control the tumor better. Breathing causes organs
and tissues, including the tumor, to move within the chest. Active breathing control may
reduce the volume that needs to be treated. Drugs used in chemotherapy, such as paclitaxel
and carboplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Giving image-guided adaptive radiation therapy
using active breathing control with chemotherapy and simultaneous integrated boost may be an
effective treatment for non-small cell lung cancer.